Business Description
MedPacto Inc
ISIN : KR7235980000
Share Class Description:
XKRX:235980: Ordinary SharesCompare
Compare
Traded in other countries / regions
235980.Korea IPO Date
2019-12-19Description
MedPacto Inc is a drug discovery and development company based in South Korea. It is engaged in developing anticancer drugs and medicines which focuses on therapeutics targeting cancer and autoimmune diseases. Its products are in pipeline.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 30.05 | |||||
| Equity-to-Asset | 0.85 | |||||
| Debt-to-Equity | 0.04 | |||||
| Debt-to-EBITDA | -0.09 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -45.5 | |||||
| 3-Year EPS without NRI Growth Rate | -37.9 | |||||
| 3-Year FCF Growth Rate | -39.2 | |||||
| 3-Year Book Growth Rate | -26.7 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 25.71 | |||||
| 9-Day RSI | 34.45 | |||||
| 14-Day RSI | 37.3 | |||||
| 6-1 Month Momentum % | -29.08 | |||||
| 12-1 Month Momentum % | -16.75 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.36 | |||||
| Quick Ratio | 7.36 | |||||
| Cash Ratio | 6.92 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.4 | |||||
| Shareholder Yield % | 20.84 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -46.23 | |||||
| ROA % | -38.48 | |||||
| ROIC % | -203.86 | |||||
| ROC (Joel Greenblatt) % | -688.68 | |||||
| ROCE % | -44.46 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 2.52 | |||||
| Price-to-Tangible-Book | 2.53 | |||||
| EV-to-EBIT | -3.67 | |||||
| EV-to-EBITDA | -3.94 | |||||
| EV-to-FCF | -4.31 | |||||
| Price-to-Net-Current-Asset-Value | 2.71 | |||||
| Price-to-Net-Cash | 2.92 | |||||
| Earnings Yield (Greenblatt) % | -27.28 | |||||
| FCF Yield % | -14.99 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
MedPacto Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil â‚©) | |||
| EPS (TTM) (â‚©) | -1008.37 | ||
| Beta | 1.31 | ||
| Volatility % | 77.56 | ||
| 14-Day RSI | 37.3 | ||
| 14-Day ATR (â‚©) | 273.715187 | ||
| 20-Day SMA (â‚©) | 4586 | ||
| 12-1 Month Momentum % | -16.75 | ||
| 52-Week Range (â‚©) | 4000 - 17240 | ||
| Shares Outstanding (Mil) | 33.58 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
MedPacto Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
MedPacto Inc Stock Events
| Event | Date | Price(â‚©) | ||
|---|---|---|---|---|
| No Event Data | ||||
MedPacto Inc Frequently Asked Questions
What is MedPacto Inc(XKRX:235980)'s stock price today?
The current price of XKRX:235980 is â‚©4220.00. The 52 week high of XKRX:235980 is â‚©17240.00 and 52 week low is â‚©4000.00.
When is next earnings date of MedPacto Inc(XKRX:235980)?
The next earnings date of MedPacto Inc(XKRX:235980) is .
Does MedPacto Inc(XKRX:235980) pay dividends? If so, how much?
MedPacto Inc(XKRX:235980) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers